Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000594392 | SCV000707391 | uncertain significance | not provided | 2017-03-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024814 | SCV003720519 | uncertain significance | not specified | 2022-10-26 | criteria provided, single submitter | clinical testing | The c.334A>G (p.M112V) alteration is located in exon 2 (coding exon 1) of the GPBAR1 gene. This alteration results from a A to G substitution at nucleotide position 334, causing the methionine (M) at amino acid position 112 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003952991 | SCV004770211 | likely benign | GPBAR1-related disorder | 2023-12-06 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |